HARNESSING SENESCENCE FOR HUMAN HEALTHSPAN
Atropos aims to treat aging-related diseases and cancer and improve healthspan with approved novel senescence- targeting drugs.
Atropos, the Fate whose duty it was
to cut the threads of life.
Robert S. Holzman, MD
The Legacy of Atropos, the Fate Who Cut the Thread of Life, 1998
March 17, 2020
Atropos is pleased to announce the recruitment of two individuals, Ethan Than MBA and Harsha Agarwal PhD, to our Business Development and Laboratory efforts.
Atropos is pleased to announce the recent submission of our non-provisional patent by WSGR describing the FATES platform for identification of senomodulators. >>